No Data
No Data
No Data
No Data
No Data
Gilead Sciences Likely to Record IPR&D Hit on Q1 Non-GAAP Earnings, Oppenheimer Says
Gilead Sciences (GILD) could see a "large" in-process research and development hit on its Q1 non-GAAP earnings due to transactions during the period, Oppenheimer said in a note emailed Friday. In Marc
MT Newswires12:18 ET
Gilead Sciences Is Maintained at Outperform by Oppenheimer
Gilead Sciences Is Maintained at Outperform by Oppenheimer
Dow JonesApr 19 11:07 ET
Express News | Oppenheimer Maintains Outperform on Gilead Sciences, Maintains $105 Price Target
Moomoo 24/7Apr 19 10:57 ET
Gilead Sciences Analyst Ratings
Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating 04/19/2024 57.97% Oppenheimer $105 → $105 Maintains Outperform 04/17/2024 12.83% UBS $81 → $75 Maintains N
BenzingaApr 19 10:56 ET
A Closer Look At Gilead Sciences, Inc.'s (NASDAQ:GILD) Impressive ROE
Many investors are still learning about the various metrics that can be useful when analysing a stock. This article is for those who would like to learn about Return On Equity (ROE). We'll use ROE to
Simply Wall StApr 19 10:02 ET
FDA Mandates "Boxed Warning" For Bristol Myers, Johnson & Johnson CAR-T-Based Blood Cancer Therapies
Following an investigation announced in November last year, the FDA said on Thursday that it would now require boxed warnings—the highest safety-related caution for medications—for all chimeric antige
BenzingaApr 19 09:28 ET
Pumpui : Just buy and hold. The gilead news is worth it. Plus any breakthru in cancer treatment for biohealth will be huge. I am holding
RockaphobicOP Pumpui:
Absolutely! I can't help but feel a bit of confidence. With such promising news, coupled with the fact that Vanguard is one of the 52 institutional shareholders. Sign me up!
GL!
No Data
No Data